Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Feb 1;10(2):182-187.
doi: 10.1001/jamacardio.2024.3767.

Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation

Jwan A Naser  1 , Tomonari Harada  1 , Yogesh N Reddy  1 , Sorin V Pislaru  1 , Hector I Michelena  1 , Christopher G Scott  2 , Austin M Kennedy  2 , Patricia A Pellikka  1 , Vuyisile T Nkomo  1 , Mackram F Eleid  1 , Barry A Borlaug  1
Affiliations
Comment

Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation

Jwan A Naser et al. JAMA Cardiol. .

Abstract

Importance: Secondary tricuspid regurgitation (STR) is observed in multiple cardiac and pulmonary diseases. Heart failure with preserved ejection fraction (HFpEF) is a common cause of STR that may be overlooked, along with precapillary etiologies of pulmonary hypertension (PH).

Objectives: To investigate the prevalence of HFpEF and precapillary PH in patients with severe STR of undefined etiology (isolated STR) referred for exercise right heart catheterization (RHC), and to evaluate the performance of noninvasive measures to identify HFpEF.

Design, setting, and participants: This retrospective cross-sectional study included consecutive adults with severe STR in the absence of EF less than 50%, hemodynamically significant left-sided valve disease, congenital heart disease, infiltrative or hypertrophic cardiomyopathy, pericardial disease, or prior cardiac procedures who underwent rest-and-exercise RHC between February 2006 and June 2023 at Mayo Clinic and transthoracic echocardiography less than 90 days prior. Diastolic dysfunction (DD) was defined by at least 3 of 4 or 2 of 3 abnormal diastolic parameters (medial e', medial E/e', tricuspid regurgitation [TR] velocity, left atrial volume index). HFpEF was diagnosed when pulmonary arterial wedge pressure was at least 15 mm Hg at rest, at least 19 mm Hg with feet up, or at least 25 mm Hg during exercise. Data analysis was performed from November 2023 to March 2024.

Main outcomes and measures: The prevalence of HFpEF and precapillary PH in severe isolated STR was determined, and performance of noninvasive measures to identify HFpEF was evaluated.

Results: Overall, 54 patients with severe isolated STR (mean [SD] age, 70.8 [12.5] years; 34 [63%] female) were identified. The primary indication for RHC was evaluation of TR prior to potential intervention in 36 patients (67%), evaluation of PH in 13 (24%), and confirmation of HFpEF in 5 (9%). HFpEF was identified in 40 patients (74%) but was recognized prior to RHC in only 19 patients (35%). Of the 14 remaining patients without HFpEF, precapillary PH was diagnosed in 10 (71%). Guideline-defined DD was absent in 24 patients (60%) who were subsequently diagnosed with HFpEF. Left atrial emptying fraction (area under the receiver operating characteristic curve [AUC] = 0.90; 95% CI, 0.82-0.98) and strain (AUC = 0.91; 95% CI, 0.83-0.99) had robust discrimination for HFpEF.

Conclusions and relevance: The findings suggest that HFpEF is underdiagnosed and should be rigorously evaluated for in patients with severe isolated STR, along with precapillary PH, as both have distinct requirements for management. Resting DD based on current guidelines is insufficiently sensitive in these patients, indicating a pressing need for other noninvasive diagnostic tools, such as left atrial function assessment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Michelena reported personal fees from ARTIVION outside the submitted work. Dr Borlaug reported serving as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations and being named inventor (US patent 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Hahn RT. Tricuspid regurgitation. N Engl J Med. 2023;388(20):1876-1891. doi:10.1056/NEJMra2216709 - DOI - PubMed
    1. Topilsky Y, Maltais S, Medina Inojosa J, et al. . Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12(3):433-442. doi:10.1016/j.jcmg.2018.06.014 - DOI - PubMed
    1. Hahn RT, Lindenfeld J, Böhm M, et al. . Tricuspid regurgitation in patients with heart failure and preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol. 2024;84(2):195-212. doi:10.1016/j.jacc.2024.04.047 - DOI - PubMed
    1. Nagueh SF, Smiseth OA, Appleton CP, et al. . Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. doi:10.1016/j.echo.2016.01.011 - DOI - PubMed
    1. Lang RM, Badano LP, Mor-Avi V, et al. . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003 - DOI - PubMed

MeSH terms